SLC5A2 and polyneuropathy: Symmetric polyneuropathy was recorded in 11 trials (5, 3, 1, and 2 with canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, respectively) for an amount of 229 events with SGLT2-is versus 166 events with comparators, thus resulting in a pooled RRMH of 1.17 [0.82–1.65] (Figure 8).